Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Onyx HealthcareROCO:6569 -0.98%73 EV-to-EBITDA is 17.21 as of Sep. 03, 2026, which is 4% above its 10-year median of 16.50. GuruFocus rates ROCO:6569 with a GF Score™ of 73/100 and a GF Value™ of NT$136.01 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 514 Healthcare Providers & Services companies, Onyx Healthcare ranks worse than 70.43% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Onyx Healthcare's enterprise value is NT$4,020 Mil.
Onyx Healthcare's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$234 Mil. Therefore, Onyx Healthcare's EV-to-EBITDA for today is 17.21.
The historical rank and industry rank for Onyx Healthcare's EV-to-EBITDA or its related term are showing as below:
ROCO:6569'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.15 Med: 16.5 Max: 33.76
Current: 17.21
During the past 13 years, the highest EV-to-EBITDA of Onyx Healthcare was 33.76. The lowest was 5.15. And the median was 16.50.
ROCO:6569's EV-to-EBITDA is ranked worse than 70.43% of 514
companies
in the Healthcare Providers & Services industry
Industry Median: 10.44
vs ROCO:6569: 17.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Onyx Healthcare's PE Ratio (TTM) for today is calculated as:
Onyx Healthcare's share price for today is NT$91.10.
Onyx Healthcare's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$4.690.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Onyx Healthcare's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6569 vs VEEV, BTSG, TEM: EV-to-EBITDA Comparison
For the Health Information Services subindustry, Onyx Healthcare's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Onyx Healthcare EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Onyx Healthcare's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Onyx Healthcare's EV-to-EBITDA falls into.
Onyx Healthcare's current Enterprise Value is NT$4,020 Mil.
Onyx Healthcare's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$234 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Onyx Healthcare (ROCO:6569) has a EV-to-EBITDA of 17.21 as of Sep. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Onyx Healthcare. This is near median its historical median of 16.50. Over the past decade, Onyx Healthcare's EV-to-EBITDA has ranged from 5.15 to 33.76. According to the industry distribution chart, Onyx Healthcare ranks #362 out of 514 companies in the Healthcare Providers & Services industry, placing it in the top 70.4%.
Is Onyx Healthcare's EV-to-EBITDA too high?
Onyx Healthcare's current EV-to-EBITDA of 17.21 is near median its 10-year median of 16.50. Over the past 10 years, this metric has ranged from a low of 5.15 to a high of 33.76. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.44. Onyx Healthcare's value of 17.21 is 64.8% above this industry median. Based on the distribution chart, Onyx Healthcare ranks #362 out of 514 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Onyx Healthcare has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Onyx Healthcare's EV-to-EBITDA compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Onyx Healthcare ranks #362 out of 514 companies for EV-to-EBITDA. This places Onyx Healthcare in the lower half of its industry. The industry median EV-to-EBITDA is 10.44. Onyx Healthcare's value of 17.21 is 64.8% above this benchmark. Historically, Onyx Healthcare's own EV-to-EBITDA has ranged from 5.15 to 33.76 over the past decade. While the company's 10-year median is 16.50 vs. the industry median of 10.44, Onyx Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.44, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Onyx Healthcare's current EV-to-EBITDA of 17.21 is 64.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Onyx Healthcare. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Onyx Healthcare's current EV-to-EBITDA is 17.21, which is near median its own 10-year median of 16.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Onyx Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Onyx Healthcare (ROCO:6569) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$136.01, compared to a current price of NT$91.10 — trading 33% below its estimated fair value. The current EV-to-EBITDA is 17.21, which is near median its 10-year median of 16.50 and 64.8% above the Healthcare Providers & Services industry median of 10.44. Onyx Healthcare's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Onyx Healthcare (ROCO:6569), the current EV-to-EBITDA is 17.21 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Onyx Healthcare (ROCO:6569) Overvalued in 2026?
Based on GuruFocus' analysis, Onyx Healthcare stock appears to be undervalued.
The current stock price of NT$91.10 is trading 33% below its estimated GF Value™ of NT$136.01.
GuruFocus considers Onyx Healthcare to be Significantly Undervalued.
Key valuation signals for ROCO:6569:
EV-to-EBITDA: 17.21 (near median its 10-year median of 16.50)
GF Value™: NT$136.01 vs. price of NT$91.10 (33% below fair value)
Industry Position: 64.8% above the Healthcare Providers & Services median (#362 of 514)
No single metric tells the full story. See the ROCO:6569 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Onyx Healthcare Inc is engaged in designing, manufacturing, and trading of medical computers and peripherals. The company provides medical products such as AI Ready Medical PC and Tablet, Medical PC & Monitor for Digital OR (ACCEL), Telemedicine, Medical Cart Computer(Venus), Medical Power Panel PC (Mini Venus), Power Bank (UPower), Battery Management System (ORION), Mobile Medical Tablet (MD), Professional Medical All in One PC (ZEUS), etc. It operates in Taiwan, the United States, Europe, and Other countries and generates maximum revenue from Taiwan.
73GF Score
Get the complete analysis for ROCO:6569
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6569 has been successfully added to your 
